<DOC>
	<DOCNO>NCT02258867</DOCNO>
	<brief_summary>The objective study assess efficacy safety gevokizumab treat Behcet 's disease uveitis ( BDU ) .</brief_summary>
	<brief_title>Efficacy Safety Study Gevokizumab Treat Behcet 's Disease Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Behcet Syndrome</mesh_term>
	<criteria>Have characteristic Behcet 's disease consistent International Criteria Behcet 's disease Have document history active uveitis without retinal vasculitis within past 12 month Best correct visual acuity ( BCVA ) &gt; = 20 ETDRS letter eye baseline Effective contraceptive measure Infectious uveitis masquerade syndrome End stage ocular disease History allergic anaphylactic reaction monoclonal antibody Active tuberculosis disease History recurrent infection predisposition infection ; active ocular infection Pregnant nursing woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Behcet 's Disease Uveitis</keyword>
	<keyword>Behcet 's Disease</keyword>
</DOC>